Merck recently settled a patent dispute with Bristol-Myers Squibb and Ono Pharmaceutical over its highly effective cancer treatment drug Keytruda. As part of the settlement Merck will pay $625m as well as royalties to Bristol-Myers Squibb and Ono Pharmaceutical. The royalties are to be split between Bristol-Myers Squibb (75%) and Ono Pharmaceutical (25%).
The outcome has been welcomed as it acknowledged the scientific discoveries Bristol-Myers Squibb and Ono Pharmaceutical made and had patented as early innovators.
Source: http://buff.ly/2jIeFzs
Summary
Article Name
Merck, Bristol-Myers Squibb and Ono Pharmaceutical have Settled Keytruda Patent Dispute
Description
Merck recently settled a patent dispute with Bristol-Myers Squibb and Ono Pharmaceutical over its highly effective cancer treatment drug Keytruda.
Author
Dawn Ellmore
Publisher Name
Dawn Ellmore Employment
Publisher Logo
